I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The prevalence of venous thromboembolism (VTE) in patients undergoing assisted reproduction (0.1--0.2%)\[[@ref1]\] is ten times higher than the general population (2.2/10,000).\[[@ref2]\] This risk is increased to 100-fold in patients who develop ovarian hyperstimulation (1.7%).\[[@ref1]\] Although the absolute numbers of VTE events in assisted reproduction are low, it can be potentially fatal with serious morbidity or mortality. With increasing use of assisted reproductive techniques (ARTs), especially in women with advanced age, obesity, and smoking, it is important for clinicians to assess risk of VTE in patients and to adopt appropriate risk-reduction strategies to make treatment safer.

In this study, we report a case with a high risk of VTE and discuss the key areas in ART that can aggravate the risk of VTE and the various preventive measures that can be adopted to reduce the risk to that of natural conception.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 26-year-old female patient presented to our fertility clinic with 3 years of primary infertility. Her menstrual cycles were irregular with cycles every 60--90 days. Her body mass index was 27 and she was a known hypothyroid on 100 mcg levothyroxine. On investigations, her pelvic scan showed a normal uterus and bilateral polycystic ovaries. Her anti-Müllerian hormone was 5.6 ng/ml. Her husband was 36 years of age and a software professional. He was a nonsmoker and a teetotaller. He had no significant past medical or surgical history. His semen analysis revealed severe oligoasthenoteratospermia (volume 2 ml, 3 million/ml; 20% progressive motility; 1% normal forms). In view of severe male factor, relevant investigations were done and they were planned for *in vitro* fertilization-intracytoplasmic sperm injection (IVF-ICSI).

She gave a history of cortical venous thrombosis following oral contraceptive intake at the age of 22 years. After intake of five tablets, she had severe headache and vomiting. A magnetic resonance imaging then had revealed cerebral venous sinus thrombosis affecting the entire superior sagittal sinus. She had been treated with therapeutic anticoagulation and was on oral anticoagulant for 6 months. Her thrombophilia workup was as follows: anticardiolipin antibodies (IgG and IgM) negative, anti-β~2~ glycoprotein 1 negative, lupus anticoagulant positive but repeat negative, protein C, protein S, antithrombin III, factor V Leiden mutation, and homocysteine normal.

Previous history of venous thrombosis made her high risk for thromboembolism during IVF in view of the changes in coagulation parameters due to ovarian stimulation. In an attempt to reduce chances of ovarian hyperstimulation, an antagonist cycle with mild stimulation was planned. She was started on 150 IU recombinant follicle-stimulating hormone (FSH, Gonal F, Merck Serono, Switzerland) from day 2 of cycle. Prophylactic anticoagulation with enoxaparin 40 IU daily was commenced along with the stimulation. Gonadotropin releasing hormone antagonist Cetrorelix 0.25 mg daily was started on day 6 of stimulation. On day 10 of stimulation, her serum estradiol was 3100 pg/ml and \>3 follicles were \>17 mm in diameter. In an attempt to avoid exposure to human chorionic gonadotropin (hCG), which is known to cause a greater impact on coagulation parameters, GnRH agonist (injection triptorelin 0.2 mg s/c) was administered as final trigger and egg retrieval was done 35 h posttrigger. Sixteen oocytes were obtained, 15 were mature, ICSI was done and 14 oocytes were fertilized. Semen parameters were 2 million/ml with 20% progressive motility. The patient was planned for Single embryo transfer (SET) and hence embryos were grown to blastocyst stage and four good-quality blastocysts were frozen. The prophylactic anticoagulation was stopped on the day of egg retrieval and restarted the day after. The patient did not show any signs of ovarian hyperstimulation.

She was planned for an FET after 2 months. Since her cycles were irregular, a natural cycle FET was not possible and a hormone replacement cycle was planned. She was started on transdermal exogenous estrogen as they are known to have a lesser impact on coagulation parameters.\[[@ref3]\] Prophylactic anticoagulation was started with exogenous estrogen. When her endometrial thickness reached an optimal thickness of 8.5 mm, she was started on exogenous progesterone and an FET was planned. Single blastocyst transfer was performed and beta-hCG was positive after 14 days of embryo transfer. Her anticoagulation was continued during pregnancy and postpartum. She delivered a healthy baby girl weighing 2.6 kg at 37-week pregnancy.

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

This case highlights the key areas in the IVF treatment protocol which increase the risk of VTE and which may be modified to the reduce risk. The assessment of risk before commencement of treatment, use of mild stimulation, antagonist protocol, avoiding ovarian hyperstimulation, use of GnRH agonist trigger and avoiding exposure to hCG, FET in a natural cycle, single embryo transfer, avoiding multiple pregnancy, and use of prophylactic or therapeutic anticoagulation are measures for risk reduction.\[[@ref4]\]

*In vitro* fertilization and increased risk of thromboembolism {#sec2-1}
--------------------------------------------------------------

A relationship between ovarian stimulation and thrombosis was first suggested in 1965,\[[@ref5]\] and following this, over 100 publications have reported the same complication.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\] Large-cohort studies have reported increased risk of VTE throughout pregnancy and the postpartum period in IVF pregnancies, though the absolute numbers are low.\[[@ref15][@ref16][@ref17]\] A recent systematic review has confirmed that the antepartum risk of VTE after IVF is doubled (odds ratio, 2.18; 95% confidence interval, 1.63--2.92) in comparison with the background normal pregnant population.\[[@ref18]\] The incidence of VTE has been reported as 0.1%--0.5% of all IVF cycles started and the risk of arterial thrombosis is much lower. Nearly 70% of reported cases are venous thrombosis and 30% are arterial.\[[@ref19]\] VTE was invariably associated with occurrence of pregnancy, and on the other hand, arterial thrombosis was reported earlier and even when pregnancy was not achieved. Merely 40% of patients had coexisting thrombophilia.\[[@ref19]\] This increased risk of VTE in IVF pregnancies is due to a 5--10-fold increased risk in the first trimester. Ovarian hyperstimulation syndrome (OHSS) increases the risk of thrombosis dramatically to 100-fold or an absolute risk of 1.7%. Interestingly, the incidence of VTE was not found to be high in patients undergoing unsuccessful IVF treatment.\[[@ref20]\] The risk of VTE may be increased in women with obesity, multiple pregnancy, smoking, advanced age, hyperhomocysteinemia, and cesarean section. These known risk factors for thrombosis in spontaneous conceptions have not been studied in depth in IVF pregnancies. However, there has been no reported increased risk in FET cycles.\[[@ref1]\]

Indications for thromboprophylaxis in patients undergoing *in vitro* fertilization {#sec2-2}
----------------------------------------------------------------------------------

Thromboprophylaxis is not indicated in all patients without any risk factors.\[[@ref21]\] All women should be assessed for risk of VTE as per the Royal College of Obstetricians and Gynaecologists\[[@ref22]\] or Swedish guidelines\[[@ref21]\] before commencement of treatment, and dose and duration of thromboprophylaxis must be decided in consultation with a hematologist. Wherever thromboprophylaxis is indicated during pregnancy, it should be commenced at the start of stimulation. Patients with history of prior VTE, Antiphospholipid syndrome (APAS) without VTE or those with multiple risk factors are at high risk for thrombosis and require thromboprophylaxis during IVF stimulation and pregnancy. Patients who are very high risk for thrombosis include those with mechanical heart valves, VTE with APAS, recurrent VTE, or antithrombin deficiency.\[[@ref21][@ref22]\]

Mechanism of thrombosis in patients undergoing *in vitro* fertilization {#sec2-3}
-----------------------------------------------------------------------

The hyperestrogenism that results from ovarian stimulation is a known thrombogenic agent. It causes increase in procoagulant factors (fibrinogen, von Willebrand factor, factors VIII and V, and increased activated protein C resistance\[[@ref23]\]), enhanced activation of coagulation (D-dimer), reduced fibrinolysis (reduced tissue plasminogen activator and plasminogen activator inhibitor type I), and reduced natural anticoagulants (antithrombin III and protein S).\[[@ref24]\] Changes in von Willebrand factor and von Willebrand factor-cleaving protease have also been reported. Tissue factor pathway inhibitor values progressively and significantly decreased throughout the ovarian stimulation and negatively correlated with estradiol.\[[@ref25]\] Although these changes suggest the possible development of a prothrombotic state, the clinical relevance of these changes is unclear and the levels of most of the parameters remain within normal limits.\[[@ref26]\] Having said that, it is rare to experience VTE before administration of hCG. Of over 100 reported cases of thrombosis in IVF, only 1 case was before the administration of hCG.\[[@ref19]\] Only 3% of both arterial and VTE have been known to occur before final oocyte maturation trigger.\[[@ref26]\] Post-hCG exposure, levels of fibrinogen, and factors II, V, VII, VIII, and IX are elevated in 2 days. Although hemostatic risk is accrued during stimulation phase, final event is often attributable to exogenous hCG.\[[@ref4]\]

Modifications in *In vitro* fertilization cycle to prevent venous thromboembolism {#sec2-4}
---------------------------------------------------------------------------------

Risk factors for enhancing the probability of thrombosis in IVF include aggressive stimulation, elevated estradiol levels, hCG as a trigger, OHSS, occurrence of pregnancy, multiple pregnancy, and use of exogenous estrogen for FET.

Ovarian hyperstimulation must be prevented by use of antagonist cycle, mild stimulation, and use of GnRH agonist trigger\[[@ref4]\]Cryopreservation of all embryos and natural cycle FET avoids the use of hCG completely. If natural cycle cannot be done and stimulation is necessary, prophylactic anticoagulation should be commenced along with it\[[@ref4]\]Single embryo transfer is preferable to avoid risk of multiple pregnancyThromboprophylaxis with low-molecular-weight heparin is started along with the stimulation. On the day of oocyte retrieval, the dose can be omitted and the next dose either commenced the following day or in the evening after egg retrieval. Prophylactic or therapeutic dose is decided based on the risk factors and in association with hematologist advice\[[@ref4]\]If the patient develops OHSS and is pregnant, thromboprophylaxis should continue till 12 + 6 weeks. If not pregnant, it should be continued for 4 weeks after resolution of OHSS.\[[@ref21]\]

Special situations {#sec2-5}
------------------

### Arterial thrombosis {#sec3-1}

Arterial thromboembolism (ATE) can result in stroke, myocardial infarction, and peripheral arterial embolism. Ischemic strokes, carotid or vertebral artery occlusion, aortic or peripheral vessel thrombosis, mesenteric artery occlusion, myocardial infarction, and intracardiac thrombosis have all been reported.\[[@ref27]\] ATE occurs earlier after a mean of 10--11 days postembryo transfer. It is less likely to occur concomitant to pregnancy unlike VTE. About 90% of ATE has been seen associated with ovarian hyperstimulation, and the likelihood of concurrent thrombophilia is low at 19--26.\[[@ref26]\]

Deep vein thrombosis in a woman undergoing hormone replacement therapy for oocyte donation {#sec2-6}
------------------------------------------------------------------------------------------

Long-term hormone replacement therapy (HRT) is a known risk factor for VTE, but thrombosis in a woman receiving short course of HRT for oocyte donation has been reported.\[[@ref28]\] This must be kept in mind in women requiring short- and long-term HRT (premature ovarian failure)\[[@ref29]\] with advancing age and with comorbidities such as obesity.

Thrombosis reported in a case of ectopic pregnancy following *In vitro* fertilization {#sec2-7}
-------------------------------------------------------------------------------------

Thrombosis may occur irrespective of the site of pregnancy. A case of cerebral thrombosis was reported following a diagnosis of ectopic pregnancy.\[[@ref30]\]

Risk of thrombosis in women with cancer for fertility preservation {#sec2-8}
------------------------------------------------------------------

Cancer is one of the acquired risk factors for thrombosis, and the risk of VTE in cancer patients is 10-fold higher than the general population. Pathogenesis of thrombosis in cancer depends on direct activation of procoagulant factors by cancer cells, some thrombogenic chemotherapeutic agents (fluorouracil, cisplatin, paclitaxel, and tamoxifen), age, and type of cancer and surgery. Women with cancer referred for fertility preservation may not be a high risk for thrombosis in view of their young age, early stage of cancer, most common cancer being breast cancer (low risk for thrombosis), unlikely to experience OHSS (GnRH agonist trigger recommended for all), no embryo transfer, and no ensuing pregnancy. Hence, based on the available evidence, women undergoing fertility preservation for cancer must be informed about the risk of thrombosis but can be reassured that the magnitude of the risk is small. Systematic antithromboprophylaxis is not indicated in all patients and can be considered in those developing early OHSS (low-dose aspirin is preferred after egg retrieval to reduce the risk of early arterial thrombosis) or those who may benefit irrespective of ovarian stimulation (thrombogenic malignancies, high-dose thrombogenic chemotherapy, surgery, risk factors for thrombosis, and personal or family history of thrombosis).\[[@ref26]\]

To conclude,

The absolute numbers of thrombosis after ovarian stimulation is usually very low\[[@ref18]\]Thrombosis is more likely to occur in women who achieve pregnancy\[[@ref19]\]Thromboprophylaxis is not indicated in patients without known risk factors undergoing IVF treatment\[[@ref21]\]Administration of hCG plays a pivotal role in the occurrence of thrombosis\[[@ref19]\]Patients diagnosed with OHSS and who need hospitalization or intervention should be started on thromboprophylaxis immediately. Thromboprophylaxis should be continued until resolution of OHSS or at least until week 12 + 6 in pregnancy.\[[@ref21]\]Thromboprophylaxis can be discontinued 4 weeks after resolution of OHSS in patients that are not pregnant\[[@ref19]\]In patients where thromboprophylaxis is indicated during pregnancy, this should be initiated at the start of FSH/human menopausal gonadotropin stimulation\[[@ref21]\]Frozen embryo replacement in women with known risk factors for thrombosis should preferably be done in a natural cycle. If stimulation is considered necessary, thromboprophylaxis should be commenced at the start of stimulation\[[@ref19]\]To decrease the risk of hemorrhage at follicular aspiration, thromboprophylaxis should be withheld in the morning before a follicular aspiration and restarted in the evening.
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